Background: Circular RNAs (circRNAs) have been reported to be implicated in the pathogenesis of prostate cancer (PCa). Herein, the authors intended to explore the role and the molecular mechanism of circRNA SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 5 (circSMARCA5) in PCa. Materials and Methods: The levels of circSMARCA5, SMARCA5, miR-432, and programmed cell death 10 (PDCD10) were determined by quantitative real-time polymerase chain reaction (qRT-PCR). The circular structure and stability of circSMARCA5 were validated by qRT-PCR using Oligo dT primer, transcriptional inhibitor actinomycin D, or RNase R treatment, respectively. Cell proliferation, migration, invasion, epithelial/mesenchymal transition (EMT), and glycolysis were detected by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), transwell migration and invasion assays, western blot assay, and Glucose or Lactate Detection Kit, respectively. The target relationship between miR-432 and circSMARCA5 or PDCD10 was validated by dual-luciferase reporter assay and RNA immunoprecipitation (RIP) assay. Western blot was performed to detect the protein expression of PDCD10 in PCa cells. Results: CircSMARCA5 was aberrantly upregulated, and it was a circular and stable RNA in PCa cells. CircSMARCA5 accelerated the proliferation, metastasis, and glycolysis of PCa cells. MiR-432 was a direct target of circSMARCA5, and circSMARCA5 accelerated the development of PCa through miR-432 in PCa cells. PDCD10 was a direct target of miR-432, and PDCD10 addition reversed the inhibitory effects of miR-432 accumulation on the proliferation, metastasis, and glycolysis of PCa cells. CircSMARCA5 upregulated the expression of PDCD10 through sponging miR-432 in PCa cells. Conclusion: CircSMARCA5 deteriorated PCa through miR-432/PDCD10 axis. CircSMARCA5/miR-432/PDCD10 axis might be an underlying therapeutic target for PCa treatment.
语种:
外文
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2021]版:
大类|4 区医学
小类|4 区医学:研究与实验4 区肿瘤学4 区药学4 区核医学
最新[2025]版:
大类|4 区医学
小类|4 区医学:研究与实验4 区肿瘤学4 区药学4 区核医学
JCR分区:
出版当年[2021]版:
Q2PHARMACOLOGY & PHARMACYQ2RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGINGQ3MEDICINE, RESEARCH & EXPERIMENTALQ3ONCOLOGY
最新[2024]版:
Q2RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGINGQ3MEDICINE, RESEARCH & EXPERIMENTALQ3ONCOLOGYQ3PHARMACOLOGY & PHARMACY
第一作者机构:[1]Department of Urology Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
共同第一作者:
通讯作者:
通讯机构:[1]Department of Urology Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China.[*1]Department of Urology Surgery, the Fourth Hospital of Hebei Medical University.No. 12 Jiankang Road, Shijiazhuang 050000, China
推荐引用方式(GB/T 7714):
Dong Chunhui,Fan Bo,Ren Zongtao,et al.CircSMARCA5 Facilitates the Progression of Prostate Cancer Through miR-432/PDCD10 Axis[J].CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS.2021,36(1):70-83.doi:10.1089/cbr.2019.3490.
APA:
Dong, Chunhui,Fan, Bo,Ren, Zongtao,Liu, Bin&Wang, Yanchao.(2021).CircSMARCA5 Facilitates the Progression of Prostate Cancer Through miR-432/PDCD10 Axis.CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS,36,(1)
MLA:
Dong, Chunhui,et al."CircSMARCA5 Facilitates the Progression of Prostate Cancer Through miR-432/PDCD10 Axis".CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS 36..1(2021):70-83